| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
44,215,000 |
| Market
Cap: |
4.11(M) |
| Last
Volume: |
17,424 |
Avg
Vol: |
59,181 |
| 52
Week Range: |
$0.06 - $0.2089 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Enzon Pharmaceuticals is engaged in existing licensing arrangements with other companies primarily related to sales of certain drug products that utilize Co.'s proprietary technology. Co. has a marketing agreement relating to the drug Vicineum.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
99,550 |
99,550 |
| Total Buy Value |
$0 |
$0 |
$13,910 |
$13,910 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Classon Rolf A |
Director |
– • – |
2007-07-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,105 |
14,876 |
|
- |
|
| Renfro Phillip M |
Director |
– • – |
2007-07-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,105 |
5,511 |
|
- |
|
| Lebuhn Robert |
Director |
– • – |
2007-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,255 |
84,970 |
|
- |
|
| Ando Goran |
Director |
– • – |
2007-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,255 |
4,076 |
|
- |
|
| Micati Victor P |
Director |
– • – |
2007-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,255 |
4,076 |
|
- |
|
| Salisbury Robert C |
Director |
– • – |
2007-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,255 |
8,107 |
|
- |
|
| Classon Rolf A |
Director |
– • – |
2007-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,255 |
13,771 |
|
- |
|
| Renfro Phillip M |
Director |
– • – |
2007-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,255 |
4,406 |
|
- |
|
| Tooman Craig A |
Exec VP Finance, CFO |
• – – |
2007-05-11 |
4 |
B |
$8.19 |
$8,190 |
D/D |
1,000 |
52,000 |
2.74 |
- |
|
| Swieca Henry |
10% Owner |
– – • |
2007-04-11 |
4 |
D |
$8.22 |
$82,541 |
I/I |
(10,000) |
0 |
|
- |
|
| Swieca Henry |
10% Owner |
– – • |
2007-04-11 |
4 |
B |
$8.22 |
$82,541 |
I/I |
10,000 |
10,000 |
1.5 |
- |
|
| Swieca Henry |
10% Owner |
– – • |
2007-04-10 |
4 |
D |
$8.25 |
$84,587 |
I/I |
(10,253) |
0 |
|
- |
|
| Swieca Henry |
10% Owner |
– – • |
2007-04-10 |
4 |
B |
$8.25 |
$84,587 |
I/I |
10,253 |
10,253 |
1.5 |
- |
|
| Swieca Henry |
10% Owner |
– – • |
2007-04-09 |
4 |
D |
$8.20 |
$373,160 |
I/I |
(45,300) |
0 |
|
- |
|
| Swieca Henry |
10% Owner |
– – • |
2007-04-09 |
4 |
B |
$8.25 |
$280,500 |
I/I |
34,000 |
45,300 |
1.5 |
- |
|
| Swieca Henry |
10% Owner |
– – • |
2007-04-09 |
4 |
B |
$8.20 |
$92,660 |
I/I |
11,300 |
11,300 |
1.5 |
- |
|
| Swieca Henry |
10% Owner |
– – • |
2007-03-02 |
4 |
D |
$8.19 |
$939,719 |
I/I |
(111,552) |
0 |
|
- |
|
| Swieca Henry |
10% Owner |
– – • |
2007-03-02 |
4 |
B |
$8.20 |
$913,986 |
I/I |
110,852 |
111,552 |
1.5 |
- |
|
| Swieca Henry |
10% Owner |
– – • |
2007-03-02 |
4 |
B |
$8.19 |
$5,733 |
I/I |
700 |
700 |
1.5 |
- |
|
| Highbridge Capital Corp |
10% Owner |
– – • |
2007-02-15 |
4 |
D |
$8.71 |
$602,571 |
I/I |
(68,910) |
0 |
|
- |
|
| Highbridge Capital Corp |
10% Owner |
– – • |
2007-02-15 |
4 |
B |
$8.71 |
$339,771 |
I/I |
38,910 |
68,910 |
1.5 |
- |
|
| Highbridge Capital Corp |
10% Owner |
– – • |
2007-02-15 |
4 |
B |
$8.67 |
$260,100 |
I/I |
30,000 |
30,000 |
1.5 |
- |
|
| Buchalter Jeffrey H |
Chairman, CEO & President |
• • – |
2007-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
198,234 |
|
- |
|
| Delcampo Ralph |
EVP, Technical Operations |
• – – |
2007-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
57,601 |
|
- |
|
| Horak Ivan D |
EVP, R&D & Ch. Scientific Off. |
• – – |
2007-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
33,500 |
|
- |
|
394 Records found
|
|
Page 14 of 16 |
|
|
